| Data Sharing Statement | | |
|------------------------|---|---|
| Article Info | http://dx.doi.org/10.21037/tlcr-20-1118 | |
| Item | Question | Authors' Response (place "-" if not applicable) |
| 1 | Would you like to share data collected for your study to others? | Yes |
| 2 | If not, would you like to share the reason for your decision? | - |
| 3 | What data in particular will be shared? | Unreported clinical characteristics in this study could be obtained if with reasonable request. |
| 4 | Any other documents will be shared? Such as study protocol, statistical analysis plan, informed consent form, clinical study report, analytic code. | Statistical analysis, study protocol, and TTN sequencing panel will also be shared if requested. |
| 5 | When will data availability begin? | From the publication data. |
| 6 | When will data availability end? | One year within the publication date, since the technique or survival date may be updated over time. |
| 7 | To whom will you share the data? | Oncologist or researchers in translational medicine. |
| 8 | For what type of analysis or purpose? | For any analysis or purpose which surrounding the topic of immunotherapy or biomarker study. |
| 9 | How or where can the data/documents be obtained? | Emails could be sent to the address below to obtain the shared data: qingzhu.jia@tmmu.edu.cn |
| 10 | Any other restrictions? | We may balance the potential benefits and risks for each request then provide the data that could be shared. |